Evidence map›Paper›PMID 36115970›Full record

Observational studyBMC cancer2022

Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP.

Qian Dong, Wenxin Ou, Mei Wang, Tiantian Jiang, Yue Weng, Xi Zhou, Xiaoqiong Tang

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Qian Dong *Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China.
Wenxin Ou *Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China.
Mei WangDepartment of Hematology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China.
Tiantian JiangDepartment of Hematology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China.
Yue WengDepartment of Hematology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China.
Xi ZhouDepartment of Hematology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China.
Xiaoqiong TangDepartment of Hematology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China. txqcqmu@hospital.cqmu.edu.cn.
Chongqing Medical University · CNFirst Affiliated Hospital of Chongqing Medical University · CN

Funding

Science-Health Joint Medical Scientific Research Project of Chongqing Grant No. 2021MSXM276
6 · The paper itself

Abstract

backgroundAnthracycline-induced cardiotoxicity is an irreversible cardiac cell injury. Therefore, it's very important to identify influencing factors of anthracycline-induced subclinical cardiotoxicity (AISC). This study was designed to analyze the influencing factors of AISC in patients with diffuse large B-cell lymphoma (DLBCL) treated with the (R)-CHOP chemotherapy regimen.

methodsThis is an ongoing observational prospective clinical trial. All patients underwent conventional echocardiography and speckle tracking echocardiography at the time of enrollment and during treatment. Changes of global longitudinal peak systolic strain were assessed after 3 cycles of (R)-CHOP chemotherapy, and patients were divided into the AISC and No-AISC groups. Demographic data, clinical variables, and biochemical variables were measured. Regression models, receiver operating characteristic curve analysis, and difference values were used to explore the relationships between variables and AISC.

resultsAmong 70 patients who completed 3 cycles of (R)-CHOP chemotherapy, 26 developed AISC. In multiple logistic regression, HDL-C (P = 0.047), ApoA1 (P = 0.022), TG (P = 0.029) and e' (P = 0.008) were associated with AISC. The combination of HDL-C and NT-proBNP had the highest area under curves (AUC) for the diagnosis of AISC than HDL-C and NT-proBNP alone (AUC = 0.752, 95%CI: 0.63-0.87, P = 0.001). Between the No-AISC and AISC groups, there was no significant difference in HDL-C, ApoA1, and e' at baseline and after 3 cycles of chemotherapy, respectively. The dynamic changes of HDL-C, ApoA1, and e' from baseline to the end of the 3

conclusionsHDL-C, ApoA1, TG, and e' are independent predictive factors in DLBCL cases treated with the (R)-CHOP chemotherapy regimen. The combination of HDL-C and NT-proBNP may improve the predictive ability for AISC in patients with DLBCL administered 3 cycles of (R)-CHOP chemotherapy. Dynamic changes of HDL-C, ApoA1, and e' may be meaningful for predicting AISC.

trial registrationOur study was registered in the Chinese Clinical Trial Registry (Approval ID. ChiCTR2100054721 http://www.chictr.org.cn/showproj.aspx?proj=145082 ).

Indexed as

AnthracyclinesLymphoma, Large B-Cell, DiffuseAntibiotics, AntineoplasticCardiotoxicityHumansProspective StudiesAnthracyclinesAntibiotics, AntineoplasticAnthracyclineCardiotoxicityDiffuse large B-cell lymphomaInfluencing factor

Identifiers

PMID36115970
PMCPMC9482309
OpenAlexW4296151522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.